CD43抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD43 mouse mAb (green) and negative control (red).    

  
  

CD43. also known as leukosialin or sialophorin, is a transmembrane sialoglycoprotein predominantly expressed on the surface of leukocytes, including T cells, neutrophils, and monocytes. It plays a critical role in cell adhesion, migration, and immune regulation. Structurally, CD43 features a large extracellular domain rich in O-linked glycosylation, which modulates its interactions with ligands like selectins and siglecs. Dysregulated CD43 expression is associated with autoimmune diseases, immunodeficiency, and hematologic malignancies, making it a biomarker of interest in both research and clinical settings.

CD43-specific antibodies are essential tools for studying its function and distribution. In research, they are used in flow cytometry, immunohistochemistry, and Western blotting to characterize leukocyte subsets and activation states. Clinically, CD43 antibodies aid in diagnosing hematologic cancers, such as acute lymphoblastic leukemia and lymphoma, where abnormal CD43 expression patterns are observed. Therapeutic applications are also emerging, with CD43-targeted therapies explored in immunomodulation and CAR-T cell development. However, challenges remain due to CD43's structural complexity and variable glycosylation, which influence antibody binding specificity. Recent advances in glycoengineering and epitope mapping aim to optimize antibody performance, enhancing their diagnostic and therapeutic potential. Overall, CD43 antibodies bridge fundamental immunology with translational medicine, offering insights into disease mechanisms and novel treatment strategies.